InteractiveSwingTrading

No Where To Go But Up, First Major Competitor To Botox

Long
NASDAQ:EOLS   Evolus, Inc. Common Stock
-Top executive for Allergen , the creator of Botox, left the company to become CEO in May 2018, days before the de facto FDA approval

-More than 200 physician KOLs are invested in Evolus's parent company

-First 900 kDa neurotoxin to be filed with the FDA since Botox

-DPW-450 is projected to be 20-25% cheaper then Botox

-Approved by the FDA recently

-Massive volume spike

-Directors bought shares in the mid 30's last year. One of the directors even reported for her son who bought 1000 shares.

I feel tomorrow is the perfect entry. Yesterday was textbook profit taking. Buying the dip tomorrow (hopefully it dips further). This is a long term hold. No dilution is scheduled yet, and they have 100 million in cash as of September 30th. They also only spent 13 million in cash during the 9 months ended Sept.30th. No offering should be expected in the near future

Will possibly sell after 20% gain depending on overall market condition and changes in future projections. Their biggest problem is commercialization. Looking for fast gains like what we saw during May of last year, but we shall see.

I will conclude by referencing to an old video made a few years after the financial crisis. It is titled "buy the dip". www.youtube.com/watch?v=0akBdQa5...

-
-

-
Comment:
Perfect. Dipped in the morning, then ran 15% to $26.87.
Comment:
Kind of regret using the weekly now lol
Comment:
$27.70!!!
Comment:
2:41pmEST $28.35. I'm posting the prices because I didn't use the daily. Again, used the weekly because I like this for a longer term hold, but as always depends on a lot of things. I never have a problem taking big profits quickly
Comment:
$29.30 AH

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.